Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2

被引:61
|
作者
Otyepka, M
Krystof, V
Havlícek, L
Siglerová, V
Strnad, M
Koca, J
机构
[1] Masaryk Univ, Fac Sci, Lab Biomol Struct & Dynam, CS-61137 Brno, Czech Republic
[2] Palacky Univ, Fac Sci, Dept Inorgan & Phys Chem, Olomouc 77146, Czech Republic
[3] Palacky Univ, Fac Sci, Lab Growth Regulators, Olomouc 78371, Czech Republic
[4] Inst Expt Bot, Olomouc 78371, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Cent Radioisotope Lab, Prague 12108 2, Czech Republic
[6] Inst Expt Bot, Isotope Lab, Prague 14220 4, Czech Republic
关键词
D O I
10.1021/jm990506w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1-cdk8) and a regulatory subunit (cyclin A-H). Purine-like inhibitors of cyclin-dependent kinases have recently been found to be of potential use as anticancer drugs. Rigid and flexible docking techniques were used for analysis of binding mode and design of new inhibitors. X-ray structures of three (ATP, olomoucine, roscovitine) cdk2 complexes were available at the beginning of the study and were used to optimize the docking parameters. The new potential inhibitors were then docked into the cdk2 enzyme, and the enzyme/inhibitor interaction energies were calculated and tested against the assayed activities of cdk1 (37 compounds) and cdk2 (9 compounds). A significant rank correlation between the activity and the rigid docking interaction energy has been found. This implies that (i) the rigid docking can be used as a tool for qualitative prediction of activity and (ii) values obtained by the rigid docking technique into the cdk2 active site can also be used for the prediction of cdk1 activity. While the resulting geometries obtained by the rigid docking are in good agreement with the X-ray data, the flexible docking did not always produce the same inhibitor conformation as that found in the crystal.
引用
收藏
页码:2506 / 2513
页数:8
相关论文
共 50 条
  • [41] Cyclin-dependent kinase inhibitors in malignant hematopoiesis
    Schirripa, Alessia
    Sexl, Veronika
    Kollmann, Karoline
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Selectivity and potency of cyclin-dependent kinase inhibitors
    Sridhar, J
    Akula, N
    Pattabiraman, N
    AAPS JOURNAL, 2006, 8 (01): : E204 - E221
  • [43] Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
    Law, Mary E.
    Corsino, Patrick E.
    Narayan, Satya
    Law, Brian K.
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 846 - 852
  • [44] Cyclin-dependent kinase inhibitors: The age of crystals
    Pines, J
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1332 (01): : M39 - M42
  • [45] Cyclin-dependent kinase inhibitors and human cancer
    Kamb, A
    CYCLIN DEPENDENT KINASE (CDK) INHIBITORS, 1998, 227 : 139 - 148
  • [46] Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors
    Wang, Fangfang
    Ma, Zhi
    Li, Yan
    Zhu, Shanna
    Xiao, Zhengtao
    Zhang, Hong
    Wang, Yonghua
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2011, 30 : 67 - 81
  • [47] Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
    Anderson, Malcolm
    Andrews, David M.
    Barker, Andy J.
    Brassington, Claire A.
    Breed, Jason
    Byth, Kate F.
    Culshaw, Janet D.
    Finlay, M. Raymond V.
    Fisher, Eric
    McMiken, Helen H. J.
    Green, Clive P.
    Heaton, Dave W.
    Nash, Ian A.
    Newcombe, Nicholas J.
    Oakes, Sandra E.
    Pauptit, Richard A.
    Roberts, Andrew
    Stanway, Judith J.
    Thomas, Andrew P.
    Tucker, Julie A.
    Walker, Mike
    Weir, Hazel M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5487 - 5492
  • [48] Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
    Guan, Haixing
    Du, Yongli
    Han, Weiwei
    Shen, Jingkang
    Li, Qunyi
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (05) : 646 - 657
  • [49] A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
    Gucky, Tomas
    Jorda, Radek
    Zatloukal, Marek
    Bazgier, Vaclav
    Berka, Karel
    Reznickova, Eva
    Beres, Tibor
    Strnad, Miroslav
    Krystof, Vladimir
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (15) : 6234 - 6247
  • [50] CYCLIN-DEPENDENT KINASE-2 (CDK2) IN THE MURINE CDC2 KINASE TS MUTANT
    YASUDA, H
    NAKATA, T
    KAMIJO, M
    HONDA, R
    NAKAMURA, M
    NINOMIYATSUJI, J
    YAMASHITA, M
    NAGAHAMA, Y
    OHBA, Y
    SOMATIC CELL AND MOLECULAR GENETICS, 1992, 18 (05) : 403 - 408